One elopement is one too many for busy tech innovators.
This long-term care provider keeps the lights on without throwing sleep cycles off
By
Aaron Dorman
Nov 10, 2023
Special lighting systems can help maintain seniors’ circadian rhythms and sleep cycles, one LTC operator says.
‘Dementia-capable’ workforce a key to changing trajectory of disease: report
By
Lois A. Bowers
Oct 30, 2019
Building a “dementia-capable” workforce across the care continuum is one of five recommendations that could change the trajectory of the disease, which could affect 13 million people and lead to an...
Pandemic may cause increase in need for LTC for people living with dementia
By
Amy Novotney
Sep 02, 2021
The ongoing COVID-19 pandemic could cause a significant rise in the number of people living with dementia, according to a group representing more than 100 Alzheimer’s and dementia associations globally....
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
AI ‘promising’ for use in geriatrics, but ethical concerns remain, researchers say
By
Aaron Dorman
Sep 22, 2023
A new meta-study on using AI within geriatrics praises AI as a “valuable asset” but still warns about the need for future research and potential ethical concerns.
Study unearths predictive features of Alzheimer’s disease
By
John O'Connor
Jan 31, 2019
Researchers at the University of California have used algorithms to identify potential blood-based markers of Alzheimer’s disease. The discovery could lead to earlier diagnoses and spur non-invasive...
US life expectancy drops for second year thanks to COVID-19, drug overdoses: CDC
By
Kimberly Bonvissuto
Jan 03, 2023
Life expectancy in the United States fell for a second consecutive year due to COVID-19 deaths and drug overdoses, falling to the shortest lifespan since 1996, according to a recent report from the Centers...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
FDA approves first drug meant to ease Alzheimer’s disease-llnked agitation
May 11, 2023
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo.